Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CK-3773274 - Tablets
CK-3773274 · 1 trial · 1 indication
Participant incidence of reported AEs to determine the safety and tolerability of aficamten in participants with HCM.
Participant incidence of LVEF \< 50% as assessed by the core laboratory assessment.
Participant incidence of reported SAEs to determine the safety and tolerability of aficamten in participants with symptomatic HCM.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 (oHCM) - Aficamten | EXPERIMENTAL | Participants received CK-3773274 doses of 5 - 15 mg once daily with dose levels guided by echocardiography assessments for up to 10 weeks |
| Cohort 1 (oHCM) - Placebo | PLACEBO_COMPARATOR | Participants received placebo once daily for up to 10 weeks |
| Cohort 2 (oHCM) - Aficamten | EXPERIMENTAL | Participants received CK-3773274 doses 10 - 30 mg once daily with dose levels guided by echocardiography assessments for up to 10 weeks |
| Cohort 2 (oHCM) - Placebo | PLACEBO_COMPARATOR | Participants received placebo once daily for up to 10 weeks |
| Cohort 3 (oHCM) - Aficamten & Background Disopyramide | EXPERIMENTAL | Participants received CK-3773274 doses 5 - 15 mg once daily with dose levels guided by echocardiography assessments for up to 10 weeks while taking disopyramide |
| Cohort 4 (nHCM) - Aficamten | EXPERIMENTAL | Participants received CK-3773274 doses of 5 - 15 mg once daily with dose levels guided by echocardiography assessments for up to 10 weeks |
| Name | Type | Description |
|---|---|---|
| CK-3773274 (5 - 15 mg) | DRUG | CK-3773274 tablets administered orally once daily |
| CK-3773274 (10 - 30 mg) | DRUG | CK-3773274 tablets administered orally once daily |
| Placebo for CK-3773274 | DRUG | Placebo administered orally once daily |
Inclusion Criteria * Males and females between 18 and 85 years of age at screening. * Body weight is ≥45 kg at screening. * Diagnosed with HCM per the following criteria: * Has left ventricular (LV) hypertrophy with non-dilated LV chamber in the absence of other cardiac disease. * Has minimal ...
CK-3773274 is an investigational small molecule being developed for the treatment of hypertrophic cardiomyopathy (HCM), a cardiovascular condition. It is not yet approved for any indication and remains in clinical development. The drug is being studied in adults with HCM to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics.
CK-3773274 targets cardiac myosin, a protein involved in heart muscle contraction. By modulating cardiac myosin, the drug aims to reduce excessive contractility associated with hypertrophic cardiomyopathy. This mechanism is distinct from other HCM therapies that target different pathways.
CK-3773274 is being developed by Cytokinetics, Incorporated, a biopharmaceutical company traded on the Nasdaq under the ticker CYTK. Cytokinetics focuses on therapies for cardiovascular and neuromuscular diseases.
CK-3773274 is in Phase 2 clinical development. A completed Phase 2 trial, NCT04219826, evaluated the drug in adults with hypertrophic cardiomyopathy. The drug is investigational and has not been approved by the FDA or any regulatory agency.
CK-3773274 has been studied in one completed Phase 2 trial, NCT04219826, titled "Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy." The trial enrolled 96 participants across the United States, Italy, Netherlands, and Spain.